- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kiniksa Pharmaceuticals Ltd (KNSA)
Kiniksa Pharmaceuticals Ltd stock price live, this page displays NASDAQ KNSA stock exchange data. View the KNSA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kiniksa Pharmaceuticals Ltd real time stock price chart below.
What Is the Kiniksa Pharmaceuticals Ltd Stock Price Today?
The Kiniksa Pharmaceuticals Ltd stock price today is 31.98.
What Is the Stock Symbol for Kiniksa Pharmaceuticals Ltd?
The stock symbol for Kiniksa Pharmaceuticals Ltd is ""KNSA.""
What Stock Exchange Does Kiniksa Pharmaceuticals Ltd Trade On?
Kiniksa Pharmaceuticals Ltd is listed and trades on the NASDAQ stock exchange.
Is Kiniksa Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Kiniksa Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KNSA quote. (ISIN: GB00BRXB0C07)
What Is the Kiniksa Pharmaceuticals Ltd Stock Price Today?
The Kiniksa Pharmaceuticals Ltd stock price today is 31.98.
What Is the Stock Symbol for Kiniksa Pharmaceuticals Ltd?
The stock symbol for Kiniksa Pharmaceuticals Ltd is ""KNSA.""
What Stock Exchange Does Kiniksa Pharmaceuticals Ltd Trade On?
Kiniksa Pharmaceuticals Ltd is listed and trades on the NASDAQ stock exchange.
Is Kiniksa Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Kiniksa Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KNSA quote. (ISIN: GB00BRXB0C07)
NASDAQ
Currency in USD
31.98
+1.72(+5.68%)
Closed·
Pre Market
38.99+7.01(+21.92%)
·
Fair Value
An estimate of a Kiniksa Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.04
32.15
52 wk Range
17.82
32.15
KNSA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Pre-Market activity
Fair Value
An estimate of a Kiniksa Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.0432.15
52 wk Range
17.8232.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KNSA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Kiniksa Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
45.17
Upside
+41.23%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Kiniksa Pharmaceuticals Ltd Company Profile
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Compare KNSA to Peers and Sector
Metrics to compare | KNSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKNSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 494.8x | −3.4x | −0.5x | |
PEG Ratio | 3.42 | −0.10 | 0.00 | |
Price/Book | 4.8x | 2.6x | 2.6x | |
Price / LTM Sales | 4.5x | 10.5x | 3.3x | |
Upside (Analyst Target) | 40.7% | 278.8% | 45.1% | |
Fair Value Upside | Unlock | 6.4% | 7.4% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 45.17
(+41.23% Upside)
Earnings
Latest Release
Jul 29, 2025
EPS / Forecast
0.23 / 0.19
Revenue / Forecast
156.79M / 145.28M
People Also Watch
FAQ
What Stock Exchange Does Kiniksa Pharma Trade On?
Kiniksa Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Kiniksa Pharma?
The stock symbol for Kiniksa Pharma is "KNSA."
What Is the Kiniksa Pharma Market Cap?
As of today, Kiniksa Pharma market cap is 2.37B.
What Is Kiniksa Pharma's Earnings Per Share (TTM)?
The Kiniksa Pharma EPS (TTM) is 0.07.
When Is the Next Kiniksa Pharma Earnings Date?
Kiniksa Pharma will release its next earnings report on 03 Nov 2025.
From a Technical Analysis Perspective, Is KNSA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Kiniksa Pharma Stock Split?
Kiniksa Pharma has split 0 times.
How Many Employees Does Kiniksa Pharma Have?
Kiniksa Pharma has 315 employees.
What is the current trading status of Kiniksa Pharma (KNSA)?
As of 04 Aug 2025, Kiniksa Pharma (KNSA) is trading at a price of 31.98, with a previous close of 31.98. The stock has fluctuated within a day range of 30.04 to 32.15, while its 52-week range spans from 17.82 to 32.15.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.